Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rituximab-ADNAB
- Development stage
- Phase 1
- Lead developer
- Vivasor
- Modality
- Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Rituximab-ADNAB** is a targeted nanoparticle anticancer product also designated **AR160**. It consists of nab-paclitaxel nanoparticles non-covalently coated with the anti-CD20 monoclonal antibody rituximab, aiming to direct paclitaxel delivery toward CD20-expressing B-cell lymphoma cells while retaining rituximab-mediated B-cell targeting and depletion. It was developed from the Mayo Clinic ADNAB platform and entered a Phase 1 investigator-initiated study in relapsed or refractory B-cell non-Hodgkin lymphoma. ([nasdaq.com](https://www.nasdaq.com/press-release/sorrento-announces-subsidiary-company-adnab-inc.-to-develop-and-commercialize-adnabtm))
- Other names
- Abraxane/rituximab 160 nm nanoparticlenab-paclitaxel/rituximab-coated nanoparticleRituximab-ADNAB
02
Targets
Beyond the preview
Go deeper on Rituximab-ADNAB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rituximab-ADNAB.